OpenCell Technologies

Executive Summary

OpenCell Technologies is a San Francisco-based drug delivery company pioneering an electromechanical intracellular delivery platform for efficient, high-throughput transfection of difficult-to-transfect cells, including primary and stem cells. Founded in 2018, the company's technology enables the delivery of nucleic acids, proteins, and other molecular payloads, addressing critical bottlenecks in gene therapy, cell therapy, and drug discovery. By overcoming the limitations of traditional viral and chemical methods, OpenCell aims to make advanced cellular therapies more effective, affordable, and scalable. The platform's potential to streamline cell and gene therapy manufacturing positions OpenCell as a key enabler in the expanding cell therapy market. Its technology could reduce production costs and improve therapeutic accessibility, offering a compelling value proposition for biopharma partners and contract manufacturers. As demand for complex cellular therapies grows, OpenCell's progress will hinge on securing strategic partnerships and funding to advance toward commercial deployment.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-tier cell therapy developer60% success
• Q2 2026Series A funding raise to support preclinical development70% success
• Q3 2026Publication of peer-reviewed efficacy data in primary cells80% success